"The Destruction of Generations": A Year of RFK Jr. at the Helm of HHS
Time：
2026-03-10 09:18
Author：
xieyijun
When women wield the scepter of life sciences
Time：
2026-03-08 15:57
Author：
xieyijun
2026: Oligonucleotides Stage a Full Breakthrough
Against the Wind, Catalysts Gather
Time：
2026-03-07 08:56
Author：
xieyijun
A 20-Year Cycle in CNS Drug Development: From Retreat to the Brink of a Boom
Exclusive Interview with Dr. Guo Fei, Founder of Shanghai Honshu Bio
Time：
2026-03-06 08:15
Author：
xieyijun
CGT at the Crossroads: New Opportunities or Darkest Hour?
Time：
2026-03-05 08:15
Author：
xieyijun
Domestic Innovative Drugs: Siege on a Billion-Dollar Blockbuster
Domestic innovators are pulling out all the stops.
Time：
2026-03-04 08:15
Author：
xieyijun
Trillion Lilly, reshaping early innovation in biotech
How do MNCs deal with themselves after harvesting low hanging fruits?
Time：
2026-03-01 13:58
Author：
xieyijun
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务